ReviewFrontiers in pediatrics2022
Severe pediatric asthma therapy: Omalizumab-A systematic review and meta-analysis of efficacy and safety profile.
Review in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 4 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Omalizumab for pediatric allergic asthma: evidence-based insights on efficacy and safety from a meta-analysis of randomized trials.Frontiers in pharmacology · 2026Pooled it
- Comparative efficacy and safety of biologic therapies in pediatric asthma: a comprehensive systematic review.Frontiers in medicine · 2026Pooled it
- The efficacy and safety of omalizumab in the treatment of asthma: an overview of systematic reviews and meta analyses.Frontiers in medicine · 2025Pooled it
- The efficacy and safety of biologics for patients with severe asthma: an umbrella review of systematic reviews and meta-analyses.Frontiers in medicine · 2025Pooled it
- Therapeutic Switching of Biological Drugs in Paediatric Severe Asthma: Experience of a Referral Centre.Biomedicines · 2026Article
- Update on Pediatric asthma management: Recent advances.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Review
- Biologics for Children and Adolescents with Asthma: A Systematic Review and Exploratory Indirect Comparative Analysis.Journal of asthma and allergy · 2026Review
- Immunotherapy for asthma.Cellular & molecular immunology · 2025Review
- Severe Paediatric Asthma Collaborative in Europe: real-world data on children on biologics.ERJ open research · 2025Article
- Advancements in Biologic Therapies for Pediatric Asthma: Emerging Therapies and Future Directions.Cureus · 2025Review
- Severe Asthma in School-Age Children: An Updated Appraisal on Biological Options and Challenges in This Age Group.Children (Basel, Switzerland) · 2025Review
- The new biologic drugs: Which children with asthma should get what?Pediatric pulmonology · 2024Review
- Severe Asthma and Biological Therapies: Now and the Future.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Omalizumab is the first biological therapy used to treat moderate-to-severe asthma and certainly the one with the highest number of publications. Methods: A systematic review and meta-analysis were performed to examine two critical outcomes of omalizumab therapy, asthma exacerbation rate, the reduction of the use of inhaled corticosteroids (ICS), and the improvement of the lung function as a secondary outcome using the following keywords in the MEDLINE database: "anti-IgE, severe asthma, children, and randomized controlled trial." We specifically selected papers that included moderate-to-severe asthma patients and collected data on children and adolescents. Results: Four RCT studies (total number of patients = 1,239) were included in the analysis. The reported data on exacerbations showed an overall improvement in the exacerbation rate with a decreased use of inhaled steroids and some other minimal clinically important difference (MCID). Conclusions: Our systematic review confirms the known findings that omalizumab therapy decreases asthma exacerbation rate and reduces background therapy inhaled steroid dose. Therefore, add-on therapy with omalizumab shows a good efficacy and safety profile, thus proving to be a useful additional therapeutic option. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier: CRD42023396785.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.